Cartesian Therapeutics (RNAC) Competitors $10.10 -0.13 (-1.27%) As of 12:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. WVE, GYRE, PAHC, MLYS, COLL, SNDX, RCUS, ELVN, AVDL, and SYREShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Wave Life Sciences (WVE), Gyre Therapeutics (GYRE), Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Wave Life Sciences Gyre Therapeutics Phibro Animal Health Mineralys Therapeutics Collegium Pharmaceutical Syndax Pharmaceuticals Arcus Biosciences Enliven Therapeutics Avadel Pharmaceuticals Spyre Therapeutics Cartesian Therapeutics (NASDAQ:RNAC) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Which has more risk and volatility, RNAC or WVE? Cartesian Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500. Does the media prefer RNAC or WVE? In the previous week, Wave Life Sciences had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 13 mentions for Wave Life Sciences and 9 mentions for Cartesian Therapeutics. Wave Life Sciences' average media sentiment score of 1.12 beat Cartesian Therapeutics' score of 0.33 indicating that Wave Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cartesian Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Wave Life Sciences 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RNAC or WVE? Cartesian Therapeutics currently has a consensus target price of $42.50, suggesting a potential upside of 320.79%. Wave Life Sciences has a consensus target price of $21.17, suggesting a potential upside of 231.25%. Given Cartesian Therapeutics' higher possible upside, research analysts plainly believe Cartesian Therapeutics is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in RNAC or WVE? Wave Life Sciences received 329 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 67.77% of users gave Wave Life Sciences an outperform vote. CompanyUnderperformOutperformCartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88%Wave Life SciencesOutperform Votes36867.77% Underperform Votes17532.23% Which has better earnings & valuation, RNAC or WVE? Wave Life Sciences has higher revenue and earnings than Cartesian Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$34.17M7.67-$219.71M-$52.83-0.19Wave Life Sciences$104.94M9.39-$57.51M-$0.84-7.61 Is RNAC or WVE more profitable? Wave Life Sciences has a net margin of -66.50% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-510.72% N/A -6.03% Wave Life Sciences -66.50%-280.57%-52.90% Do insiders and institutionals hold more shares of RNAC or WVE? 86.9% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 57.9% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryWave Life Sciences beats Cartesian Therapeutics on 12 of the 19 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.71M$6.58B$5.41B$8.53BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.199.2126.7719.96Price / Sales7.67257.57395.44121.37Price / CashN/A65.8538.2534.62Price / Book-0.126.576.874.60Net Income-$219.71M$144.25M$3.23B$248.27M7 Day Performance1.20%5.13%5.32%2.28%1 Month Performance-2.32%9.67%13.56%16.43%1 Year Performance-58.94%-0.88%17.86%8.15% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.5598 of 5 stars$10.10-1.3%$42.50+320.8%-60.4%$260.71M$34.17M-0.1964News CoverageAnalyst RevisionWVEWave Life Sciences4.4236 of 5 stars$6.60+0.2%$21.17+220.7%+2.5%$1.02B$108.30M-5.95240Positive NewsGap DownGYREGyre Therapeutics0.2805 of 5 stars$10.83+13.6%N/A-21.0%$1.02B$105.76M541.5040PAHCPhibro Animal Health3.5513 of 5 stars$24.50+9.0%$20.00-18.4%+32.1%$992.32M$1.11B51.041,860Positive NewsMLYSMineralys Therapeutics2.7745 of 5 stars$15.01+2.5%$33.00+119.9%+25.7%$973.79MN/A-4.1228COLLCollegium Pharmaceutical4.113 of 5 stars$29.56+2.3%$43.80+48.2%-12.3%$949.82M$631.45M12.74210News CoveragePositive NewsSNDXSyndax Pharmaceuticals3.8837 of 5 stars$10.99+2.7%$35.91+226.7%-47.8%$945.66M$43.72M-3.03110Positive NewsRCUSArcus Biosciences3.5937 of 5 stars$8.82+6.5%$25.67+191.2%-47.4%$933.38M$141M-2.80500Positive NewsHigh Trading VolumeELVNEnliven Therapeutics2.534 of 5 stars$19.01+3.2%$40.33+112.2%-27.6%$932.75MN/A-10.0150Earnings ReportAnalyst RevisionAVDLAvadel Pharmaceuticals2.2395 of 5 stars$9.59+2.1%$19.43+102.6%-40.3%$926.67M$169.12M-12.1470Positive NewsSYRESpyre Therapeutics2.3601 of 5 stars$14.93+5.9%$51.17+242.7%-58.2%$899.92M$890,000.00-2.00100Positive NewsGap Down Related Companies and Tools Related Companies WVE Competitors GYRE Competitors PAHC Competitors MLYS Competitors COLL Competitors SNDX Competitors RCUS Competitors ELVN Competitors AVDL Competitors SYRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAC Stock Free RNAC Stock Alerts